Valeant (Two Dermatological Products) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Valeant (Two Dermatological Products) General Information

Description

A portfolio of two generic dermatology products. The portfolio is comprised of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, used for the topical treatment of acne vulgaris and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, used for the topical treatment of multiple actinic or solar keratoses.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 2150 Saint Elzéar Boulevard
  • Laval
  • Quebec, Quebec H7L 4A8
  • Canada
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Valeant (Two Dermatological Products) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Valeant (Two Dermatological Products)‘s full profile, request access.

Request a free trial

Valeant (Two Dermatological Products) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Valeant (Two Dermatological Products)‘s full profile, request access.

Request a free trial